This protocol applies to patients with pituitary gigantism who carry a germline AIP gene mutation and whose initial treatment course — including pegvisomant-based therapy — has failed to achieve adequate control of IGF-1 excess and decreased height gain.

Clinical Scenario

Germline mutations in the AIP gene are the main known cause of pituitary gigantism and are found in approximately 29% of affected patients. This population frequently presents with large pituitary tumors that can be resistant to standard medical therapies, making durable biochemical control particularly challenging.

First-Line Failure Condition

This next-line protocol is indicated when prior therapy has not achieved its targets. First-line approaches in AIP-mutated patients may have included:

Pegvisomant as monotherapy
Pegvisomant combined with a somatostatin analog (octreotide or lanreotide)
Pegvisomant combined with cabergoline (in somatostatin analog–resistant or intolerant cases)
Surgical re-debulking to facilitate subsequent hormonal control

When these measures have not achieved adequate control of IGF-1 excess and decreased height gain, escalation to the next treatment line is warranted.

Next-Line Approach — Partial Overview

For AIP-mutated patients with large and resistant tumors who remain insufficiently controlled, a multi-somatostatin receptor ligand represents a therapeutic option at this stage. The full protocol — including patient selection criteria, monitoring parameters, and the complete treatment algorithm — is available via the link below.

References

DOI: 10.1016/B978-0-12-814537-1.00002-6

Germline mutations in the AIP gene are the main known cause of pituitary gigantism.
Among pituitary gigantism patients themselves, 29% have an AIP mutation.
On switching to treatment with pasireotide, a multi-somatostatin receptor ligand, both patients experienced control of their GH and IGF-1 hypersecretion.
These data suggest that in some AIP-mutated patients with large and resistant tumors, pasireotide therapy might be a useful option, although the diabetes mellitus that can accompany pasireotide therapy adds to the therapeutic burden.
With continued therapy over some years, significant tumor regression occurred (Fig. 12.3), and one patient stopped pasireotide without a return of elevated GH and IGF-1 and still remains controlled off treatment at this time.

View source ↗

Pituitary Gigantism with Germline AIP Mutation When First-Line Treatment Has Not Controlled IGF-1

Clinical Scenario

First-Line Failure Condition

Next-Line Approach — Partial Overview

Clinical Goals

References